Daniel L. Suzman

3.1k total citations · 2 hit papers
59 papers, 2.0k citations indexed

About

Daniel L. Suzman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Daniel L. Suzman has authored 59 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 27 papers in Oncology and 14 papers in Cancer Research. Recurrent topics in Daniel L. Suzman's work include Prostate Cancer Treatment and Research (21 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Bladder and Urothelial Cancer Treatments (12 papers). Daniel L. Suzman is often cited by papers focused on Prostate Cancer Treatment and Research (21 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Bladder and Urothelial Cancer Treatments (12 papers). Daniel L. Suzman collaborates with scholars based in United States, Australia and South Africa. Daniel L. Suzman's co-authors include Richard Pazdur, Emmanuel S. Antonarakis, Shenghui Tang, Gideon M. Blumenthal, Dickran Kazandjian, Patricia Keegan, Kirsten B. Goldberg, Sirisha L. Mushti, Kun He and Mark Avigan and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Clinical Infectious Diseases.

In The Last Decade

Daniel L. Suzman

54 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

2016 337 citations Daniel L. Suzman, Richard Pazdur et al. The Oncologist profile →
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

2022 127 citations Jaleh Fallah, Sundeep Agrawal et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel L. Suzman United States	19	1.3k	812	352	318	272	59	2.0k
Vincent van der Noort Netherlands	23	1.3k 1.0×	1.4k 1.8×	266 0.8×	294 0.9×	286 1.1×	133	2.5k
Alice Chen United States	7	1.3k 1.0×	624 0.8×	156 0.4×	346 1.1×	241 0.9×	14	1.8k
Miso Kim South Korea	25	1.2k 0.9×	710 0.9×	292 0.8×	276 0.9×	248 0.9×	87	1.7k
Nikhil I. Khushalani United States	25	1.7k 1.3×	730 0.9×	583 1.7×	556 1.7×	322 1.2×	161	2.4k
Édith Borcoman France	17	948 0.7×	419 0.5×	239 0.7×	281 0.9×	150 0.6×	50	1.3k
Christos E. Kyriakopoulos United States	19	780 0.6×	1.1k 1.4×	386 1.1×	301 0.9×	392 1.4×	84	2.0k
Ki Y. Chung United States	20	1.6k 1.3×	702 0.9×	617 1.8×	256 0.8×	267 1.0×	62	2.4k
Jessica Menis Italy	21	1.2k 0.9×	1.1k 1.4×	381 1.1×	120 0.4×	145 0.5×	76	1.9k
Erika Rijavec Italy	24	1.1k 0.8×	707 0.9×	489 1.4×	253 0.8×	146 0.5×	93	1.7k
Giovanni Schinzari Italy	27	1.5k 1.1×	761 0.9×	501 1.4×	325 1.0×	393 1.4×	116	2.2k

Countries citing papers authored by Daniel L. Suzman

Since Specialization

Citations

This map shows the geographic impact of Daniel L. Suzman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel L. Suzman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel L. Suzman more than expected).

Fields of papers citing papers by Daniel L. Suzman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel L. Suzman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel L. Suzman. The network helps show where Daniel L. Suzman may publish in the future.

Co-authorship network of co-authors of Daniel L. Suzman

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel L. Suzman. A scholar is included among the top collaborators of Daniel L. Suzman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel L. Suzman. Daniel L. Suzman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chang, Elaine, Haley Gittleman, Erik Bloomquist, et al.. (2025). The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials. JNCI Cancer Spectrum. 9(4).

Heiss, Brian L., Elaine Chang, Hee‐Koung Joeng, et al.. (2025). FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ. Clinical Cancer Research. 31(20). 4223–4229. 2 indexed citations

Fallah, Jaleh, Jianjin Xu, Chana Weinstock, et al.. (2024). Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis. Journal of Clinical Oncology. 42(14). 1687–1698. 33 indexed citations

Chang, Elaine, Chi Song, Haley Gittleman, et al.. (2024). A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma. Clinical Cancer Research. 30(15). 3282–3286. 5 indexed citations

Brave, Michael H., William F. Maguire, Chana Weinstock, et al.. (2024). FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 30(21). 4815–4821. 14 indexed citations

Fallah, Jaleh, Jianjin Xu, Hee‐Koung Joeng, et al.. (2024). False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations. JCO Precision Oncology. 8(8). e2400354–e2400354.

Fallah, Jaleh, Brian L. Heiss, Hee‐Koung Joeng, et al.. (2024). FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma. Clinical Cancer Research. 30(22). 5003–5008. 9 indexed citations

Maguire, William F., Daniel Lee, Chana Weinstock, et al.. (2024). FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 30(10). 2011–2016. 13 indexed citations

Chang, Elaine, Haley Gittleman, Erik Bloomquist, et al.. (2023). FDA pooled analysis of overall survival according to depth of response as a continuous variable in frontline advanced immuno-oncology renal cell carcinoma trials.. Journal of Clinical Oncology. 41(16_suppl). e16532–e16532.

10.

Fallah, Jaleh, Sundeep Agrawal, Haley Gittleman, et al.. (2022). FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 29(9). 1651–1657. 127 indexed citations breakdown →

11.

Brave, Michael H., Chana Weinstock, Jamie R. Brewer, et al.. (2020). An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer. Clinical Cancer Research. 26(18). 4717–4722. 20 indexed citations

12.

Markowski, Mark C., Yongmei Chen, Zhaoyong Feng, et al.. (2019). PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Clinical Genitourinary Cancer. 17(6). 470–475.e1. 33 indexed citations

13.

Suzman, Daniel L., Sundeep Agrawal, V. Ellen Maher, et al.. (2018). FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. The Oncologist. 24(4). 563–569. 138 indexed citations

14.

Markowski, Mark C., Feng Zeng, Bruce J. Trock, et al.. (2017). PSA doubling time (PSADT) and proximal PSA predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP): Implications for patient counseling and clinical trial design. Annals of Oncology. 28. v283–v284. 1 indexed citations

15.

Maughan, Benjamin L., Daniel L. Suzman, Brandon Luber, et al.. (2016). Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 78(6). 1297–1304. 21 indexed citations

16.

Suzman, Daniel L., Xian Zhou, Marianna Zahurak, Jun Lin, & Emmanuel S. Antonarakis. (2014). Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials. Prostate Cancer and Prostatic Diseases. 18(1). 49–55. 4 indexed citations

17.

Suzman, Daniel L. & Emmanuel S. Antonarakis. (2013). High-Dose Itraconazole As a Noncastrating Therapy for a Patient With Biochemically Recurrent Prostate Cancer. Clinical Genitourinary Cancer. 12(2). e51–e53. 12 indexed citations

18.

Farel, Claire E., Daniel L. Suzman, Mary McLaughlin, et al.. (2004). Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin. AIDS. 18(13). 1805–1809. 17 indexed citations

19.

Wright, Mary E., Daniel L. Suzman, Karl G. Csaky, et al.. (2003). Extensive Retinal Neovascularization as a Late Finding in Human Immunodeficiency Virus–Infected Patients with Immune Recovery Uveitis. Clinical Infectious Diseases. 36(8). 1063–1066. 18 indexed citations

20.

Polis, Michael A., Daniel L. Suzman, Christian Yoder, et al.. (2003). Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen. AIDS. 17(8). 1167–1172. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact